Dr. Zelenko’s Prescription for COVID-19

PROPHYLAXIS

TREATMENT

LINK: TheZelenkoProtocol.com


LINK: COVID Care Protocol from Eastern Virginia Medical School
The latest complete treatment protocol for doctors provided by Eastern Virginia Medical School, but does not include Hydroxychloroquine.


FROM NIH.GOV:

LINK: COVID-19 Treatment Guidelines

LINK: Corticosteroids (Including Dexamethasone)

NIH.GOV Recommendation for Patients with COVID-19

  • The COVID-19 Treatment Guidelines Panel (the Panel) recommends using dexamethasone (at a dose of 6 mg per day for up to 10 days) for the treatment of COVID-19 in patients who are mechanically ventilated (AI) and in patients who require supplemental oxygen but who are not mechanically ventilated (BI).
  • The Panel recommends against using dexamethasone for the treatment of COVID-19 in patients who do not require supplemental oxygen (AI).
  • LINK: Potential therapeutic effects of Dipyridamole in the severely ill patients with COVID-19

    Abstract

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can cause acute respiratory distress syndrome, hypercoagulability, hypertension, and multiorgan dysfunction. Effective antivirals with safe clinical profile are urgently needed to improve the overall prognosis. In an analysis of a randomly collected cohort of 124 patients with COVID-19, we found that hypercoagulability as indicated by elevated concentrations of D-dimers was associated with disease severity. By virtual screening of a U.S. FDA approved drug library, we identified an anticoagulation agent dipyridamole (DIP) in silico, which suppressed SARS-CoV-2 replication in vitro. In a proof-of-concept trial involving 31 patients with COVID-19, DIP supplementation was associated with significantly decreased concentrations of D-dimers (P < 0.05), increased lymphocyte and platelet recovery in the circulation, and markedly improved clinical outcomes in comparison to the control patients. In particular, all 8 of the DIP-treated severely ill patients showed remarkable improvement: 7 patients (87.5%) achieved clinical cure and were discharged from the hospitals while the remaining 1 patient (12.5%) was in clinical remission. KEY WORDS: Dipyridamole, SARS-CoV-2, COVID-19, Treatment, D-dimer, Severe cases


    LINK: Coronavirus: Air ionizers may be the key in fight to defeat Covid-19
    Swedish 2015 study used a portable air ionizing device to achieve 100% prevention of airborne transmitted influenza “A” between animals and a 97% inactivation of the virus.


    LINK: THE BRAZILIAN COVID KIT: Hydroxychloroquine, Azithromycin, Ivermectin, Zinc and Vitamin D for early treatment of Covid-19
    Regional Council of Medicine, Medical Association of Mato Grosso do Sul, Brazilian Medical Association, Union of Doctors

    IVERMECTIN and COVID-19

    Ivermectin does much more than just kill the virus.

    Ivermectin may interfere with the binding of the SARS-CoV-2 virus with the cell receptor on virus replication cells AND ON RED BLOOD CELLS, Reducing the blood clotting problem.

    Dr. Seheult explains:

    MORE ON IVERMECTIN:

    LINK: National University Singapore Launches Large COVID-19 Prophylaxis Study Targeting Ivermectin & HCQ

    LINK: PAPER: Ivermecin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2

    NAC (N-Acetylcysteine) Supplementation and COVID-19

    NAC (N-Acetylcysteine) Supplementation and COVID-19
    Dr. Seheult of MedCram.com


    LINK: NIH.GOV n-acetylcysteine (NAC): A potential therapeutic agent for SARS-CoV-2

    LINK: NIH.GOV Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous n-acetylcysteine (NAC)

    LINK: N-acetylcysteine as a potential treatment for novel coronavirus disease 2019

    Dr. Seheult on COVID-19 as an Endothelial Disease

    Dr. Seheult: Coronavirus Pandemic Update 63: Is COVID-19 a Disease of the Endothelium (Blood Vessels and Clots)

    This helps to explain why COVID-19 is causing strokes in younger patients.


    Large Vessel Strokes in Younger Patients Tied to COVID-19

    Five COVID-19 patients ages 33 to 49 developed acute ischemic large-vessel stroke, data from a New York City health system showed.

    https://www.medpagetoday.com/infectiousdisease/covid19/86205


    Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young

    We report five cases of large-vessel stroke in patients younger than 50 years of age who presented to our health system in New York City. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was diagnosed in all five patients.

    https://www.nejm.org/doi/full/10.1056/NEJMc2009787


    Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19

    Using an observational database from 169 hospitals in Asia, Europe, and North America, we evaluated the relationship of cardiovascular disease and drug therapy with in-hospital death among hospitalized patients with Covid-19 who were admitted between December 20, 2019, and March 15, 2020, and were recorded in the Surgical Outcomes Collaborative registry as having either died in the hospital or survived to discharge as of March 28, 2020.

    https://www.nejm.org/doi/full/10.1056/NEJMoa2007621

    Hydroxychloroquine Has about 90 Percent Chance of Helping COVID-19 Patients

    Hydroxychloroquine Has about 90 Percent Chance of Helping COVID-19 Patients

    States Association of American Physicians and Surgeons (AAPS)

    To date, the total number of reported patients treated with HCQ, with or without zinc and the widely used antibiotic azithromycin, is 2,333, writes AAPS, in observational data from China, France, South Korea, Algeria, and the U.S. Of these, 2,137 or 91.6 percent improved clinically. There were 63 deaths, all but 11 in a single retrospective report from the Veterans Administration where the patients were severely ill.

    https://finance.yahoo.com/news/hydroxychloroquine-90-percent-chance-helping-155637974.html


    Sequential CQ / HCQ Research Papers and Reports

    January to April 20, 2020

    Executive Summary Interpretation of the Data In This Report

    The HCQ-AZ combination, when started immediately after diagnosis, appears to be a safe and efficient treatment for COVID-19, with a mortality rate of 0.5% in elderly patients. It avoids worsening and clears virus persistence and contagious infectivity in most cases.

    https://docs.google.com/document/d/1545C_dJWMIAgqeLEsfo2U8Kq5WprDuARXrJl6N1aDjY/edit#


    The probabilities of clinical success using

    hydroxychloroquine with or without azithromycin +/- zinc

    against the novel betacoronavirus, SARS-CoV-2

    (Use the link below to access the table)

    https://drive.google.com/file/d/1w6p_HqRXCrW0_wYNK7m_zpQLbBVYcvVU/view

    56 Residents at Texas Nursing Home Test + for COVID-19, All But One Survive

    56 residents and 33 staff members tested positive for COVID-19 at the Resort at Texas City nursing home.

    Instead of COVID-19 killing many of the residents, as has happened at other nursing homes, Dr. Robin Armstrong treated each ill resident and staff member with hydroxycholoroquine, z-pak, and zinc at the first sign of symptoms.

    Dr. Armstrong’s prompt action saved all but one. Compare that to New York nursing homes with 50 deaths or more where the hydroxychloroquine regimen is not being used.

    See the video: Texas nursing home residents’ lives saved with hydroxychloroquine

    Dr. Robin Armstrong
    Dr. Robin Armstrong of Resort at Texas City nursing home.

    Dr. Zelenko’s prescription for COVID-19

    1- hydroxychloroquine 200mg twice a day for 5 days
    2- azithromycin 500mg once a day for five days (people with heart problems should consider a different antibiotic)
    3- zinc sulfate 220mg once a day for five days

    17-year-old Texas honor student and ROTC cadet with no underlying health conditions tragically dies from COVID-19

    Jameela Dirrean-Emoni Barber
    Jameela Dirrean-Emoni Barber dead of COVID-19 at just 17 years of age

    Why Is Hydroxychloroquine Being Demonized?

    By preventing the use of hydroxychloroquine in combination with zinc, lives are being lost.

    Prior to March 2020, hydroxychloroquine was considered relatively safe, with a rare risk of arrhythmia, but not death.

    Hydroxychloroquine, originally used as an antimalarial agent, has beneficial effects on mucocutaneous symptoms in systemic lupus erythematosus. It is also used for the skin rash of discoid lupus erythematosus. A number of rare but serious adverse reactions can occur with its use and are usually associated with long-term therapy.

    https://medsafe.govt.nz/profs/PUArticles/Sep2015/Hydroxychloroquine.htm

    Beginning in March 2020, after hydroxychloroquine in conjunction with zinc was identified as a possible treatment for COVID-19, hydroxychloroquine suddenly became deadly:

    Antimalarials widely used against COVID-19 heighten risk of cardiac arrest.
    FDA: Improper use of hydroxychloroquine, chloroquine for COVID-19 may increase risk for arrhythmias, death
    Small chloroquine study ends early in Brazil due to deaths

    A warning to those considering combination therapy with hydroxychloroquine (HCQ) for COVID-19: individually, some medications being considered have been known to put users at risk of sudden cardiac death, major U.S. medical societies said.

    In response to the new hysteria about the danger of hydroxychloroquine, the American College of Cardiology wrote this:

    Chloroquine, and its more contemporary derivative hydroxychloroquine, have remained in clinical use for more than a half-century as an effective therapy for treatment of some malarias, lupus, and rheumatoid arthritis. Data show inhibition of iKr and resultant mild QT prolongation associated with both agents.
    Despite these suggestive findings, several hundred million courses of chloroquine have been used worldwide making it one of the most widely used drugs in history, without reports of arrhythmic death under World Health Organization surveillance.

    https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19

    COVID-19 Update 59: Dr. Seheult’s Daily Regimen

    Coronavirus Pandemic Update 59: Dr. Seheult’s Daily Regimen (Vitamin D, C, Zinc, Quercetin, NAC)

    What supplements Dr. Seheult takes daily to help protect against COVID-19:

    Vitamin C
    Vitamin D: 2500 IU or 62.5 mcg per day
    Zinc 50 mg per day for a short period of time
    Quercetin 500 mg 2 times per day
    NAC (N acetyl Cysteine) 600 mg 2 times per day

    Dr. Seheult gives detailed information in the video.

    Personal Experience: How I Beat COVID-19

    Gene Dellasala of Audioholics tells how he beat COVID-19 taking hydroxychloroquine and azithromycin and zinc and talks about the side effects.

    Dr. Zelenko’s prescription for COVID-19

    1- hydroxychloroquine 200mg twice a day for 5 days
    2- azithromycin 500mg once a day for five days (people with heart problems should consider a different antibiotic)
    3- zinc sulfate 220mg once a day for five days

    WebMD: COVID-19 Clinical Trials to test cures and prevention

    WebMD presents information on a number of clinical trials taking place around the world which are testing ways to cure and prevent COVID-19.

    Clinical trials are testing hydroxychloroquine and zinc, vitamins C and D, HIV drugs Lopinavir and Ritonavir, and a mouth spray containing the antiseptic ARMS-I.

    Most of the clinical trials will have results this summer.

    WebMD on COVID-19 clinical trials


    Medmastery: Scientific explanations of how zinc is helped to enter the cell by hydroxychloroquine where the zinc then prevents virus replication:

    JJ Medicine: Chloroquine, Hydroxychloroquine & SARS-CoV-2 (COVID-19): Mechanism & Overview of Anti-Viral Effects